|
Sign In to gain access to subscriptions and/or personal tools.
|
Bisphosphonates: From Grandparents to Grandchildren
Tarak Srivastava, MD
Uri S. Alon, MD
Section of Nephrology, The Children's Mercy Hospital and University of Missouri at Kansas City, MO
Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. Bisphosphonates have been extensively used in the elderly with primary and secondary osteoporosis, Paget's disease, and hypercalcemia of malignancy. In recent years, bisphosphonates have been used to treat children acutely for resistant hypercalcemia and chronically for various metabolic bone diseases. The theoretical concerns of possible adverse effects of these drugs on the growing skeleton have not been proven to be true. In the present review, we have critically analyzed the available literature on bisphosphonate therapy in both adult and pediatric clinical trials. Although not yet approved by the FDA for use in children, bisphosphonates, from published experience, demonstrate benefit to the child with no serious adverse effects. Based on the literature analysis the review furnishes detailed recommendations and practical guidelines regarding the use of oral and intravenous bisphosphonates in children. Bisphosphonates might be the first agents to provide the pediatrician with an opportunity to treat mineral and bone disorders of childhood, which until recently did not have satisfactory therapy.
Clinical Pediatrics, Vol. 38, No. 12,
687-702 (1999)
DOI: 10.1177/000992289903801201
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Astrom, H. Jorulf, and S. Soderhall
Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta
Arch. Dis. Child.,
April 1, 2007;
92(4):
332 - 338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. P. Cagle, S. G. Waguespack, B. A. Buckingham, R. R. Shankar, and L. A. DiMeglio
Severe Infantile Hypercalcemia Associated With Williams Syndrome Successfully Treated With Intravenously Administered Pamidronate
Pediatrics,
October 1, 2004;
114(4):
1091 - 1095.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Whyte, D. Wenkert, K. L. Clements, W. H. McAlister, and S. Mumm
Bisphosphonate-Induced Osteopetrosis
N. Engl. J. Med.,
July 31, 2003;
349(5):
457 - 463.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Zeitlin, F. Rauch, H. Plotkin, and F. H. Glorieux
Height and Weight Development During Four Years of Therapy With Cyclical Intravenous Pamidronate in Children and Adolescents With Osteogenesis Imperfecta Types I, III, and IV
Pediatrics,
May 1, 2003;
111(5):
1030 - 1036.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E Astrom and S Soderhall
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta
Arch. Dis. Child.,
May 1, 2002;
86(5):
356 - 364.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. V. Sekhar, S. Culbert, W. K. Hoots, M. J. Klein, H. Zietz, and R. Vassilopoulou-Sellin
Severe Osteopenia in a Young Boy With Kostmann's Congenital Neutropenia Treated With Granulocyte Colony-Stimulating Factor: Suggested Therapeutic Approach
Pediatrics,
September 1, 2001;
108(3):
e54 - 54.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Khan, A. Licata, and D. Rogers
Intravenous Bisphosphonate for Hypercalcemia Accompanying Subcutaneous Fat Necrosis: A Novel Treatment Approach
Clinical Pediatrics,
April 1, 2001;
40(4):
217 - 219.
[PDF]
|
|
|
|
|
